We are a SPECIALTY PHARMACEUTICAL COMPANY
SOLVING THE UNSOLVED
We are on a mission to improve public health globally by providing novel therapies for unmet medical needs across ophthalmology, dermatology, and oral care.
What we do
For over two decades, our team has collaborated with major US universities to invent a technology platform that modulates metal ions in disease pathways. We have a single molecule platform with broad applicability across multiple indications.
Ophthamology
We are developing eye drops as a treatment for band keratopathy patients. Additionally, our team is advancing a topical treatment to improve vision in cataract patients.
Dermatology
We are developing an anti-inflammatory dermal lotion to topically treat lower leg edema and stasis dermatitis in patients suffering from Chronic Venous Insufficiency.
Oral Care
We have developed a toothpaste that is approved in Europe for the treatment & prevention of gingivitis & periodontitis. This product be sold under the LIVFRESH brand.
Ophthamology
We are developing eye drops as a treatment for band keratopathy patients. Additionally, our team is advancing a topical treatment to improve vision in cataract patients.
Dermatology
We are developing an anti-inflammatory dermal lotion to topically treat lower leg edema and stasis dermatitis in patients suffering from Chronic Venous Insufficiency.
Oral Care
We have developed a toothpaste that is approved in Europe for the treatment & prevention of gingivitis & periodontitis. This product be sold under the LIVFRESH brand.
Generating New Ideas. Solving Big Problems
The L1220 compound is effective against inflammation, metalo lipid-protein aggregates, and biofilms. Livionex technology enables a unique metal modulation pathway to address multiple disease modalities.
Research Studies
Patents & Applications
Partnerships & Collaborations
Approval
Our Origins
Livionex originated because of one man’s desire to restore his father’s vision. Rajiv Bhushan, one of our founders, formulated eye drops to treat his father, Arya, who was suffering from cataracts, photophobia, and dry AMD. Within six months of use, Arya was able to thread a needle. Having defied the odds, ophthalmologists at premier universities could not believe Arya’s vision improvement. Soon after, Rajiv partnered with serial entrepreneur, Amit Goswamy, to commercialize the eye drops and gain regulatory approvals. Their ultimate goal was, and still is, to improve the vision of millions.
Over the years, Rajiv and Amit discovered that the technology underlying the eye drops could be applied to other diseases, including Chronic Venous Insufficiency and Periodontitis. Livionex soon became a pharmaceutical company specializing in ophthalmology, dermatology, and oral care.
CLINICAL STAGES
L1220-E eye drops have gained FDA approval to proceed to a single claim enabling Phase III trial as the first topical treatment of Band Keratopathy. Additionally, a topical eye drop is in advanced clinical development to restore vision in patents with early to moderate Cataracts. Moreover, we plan to file INDs and initiate Phase II trials for our dermal and oral care therapies, respectively. We are seeking claims in Chronic Venous Insufficiency (CVI) for our dermal lotion, and Periodontitis for the LivFresh toothpaste in USA.
- Ophthalmology (Initiating Phase 3)
- Dermatology (Initiating Phase 2)
- Oral Care (Initiating Phase 2)
COLLABORATIONS & PARTNERSHIPS
The company is fortunate to partner and collaborate with industry leaders and leading research institutions.
ACADEMIC AWARDS & GRANTS
UNIVERSITY PARTNERSHIPS
Free iron and calcium play a key role in oxidative stress and pathways leading to multiple diseases. The Company’s proprietary small molecule technology modulates intracellular metal ions, such as calcium and iron in the body. While metal chelation is a well-understood scientific process, its therapeutic effectiveness in clinical settings has been limited primarily due to the inability of chelator molecules to permeate across negatively charged biological tissues and cell membranes. Livionex has solved the problem of delivering chelators at therapeutic levels, enabling drug development across multiple areas of research.
Our Team
With decades of experiences spanning across diverse industries and academia, the Livionex team is comprised of the best and brightest.
Amit Goswamy
CEO
Serial entrepreneur with multiple exits of VC-backed companies. Indian Institute of Technology & Stanford MBA.
Rajiv Bhushan
CHIEF SCIENTIST
Richard Trevino, PhD
HEAD OF MANUFACTURING
25+ years of managerial experience in manufacturing for pharmaceutical companies including Amgen, Johnson & Johnson, and Onyx Pharmaceuticals. University of Texas PhD in Biochemistry.
Brian Novy, DDS, FADI, FACD
LEAD CLINICIAN
Past Chair of ADA Council on Scientific Affairs Subcommittee on Caries Management
Jerry Gin, PhD
CHAIRMAN
Founder Oculex Pharma (acquired by Allergan) & ChemTrak (IPO). UC Berkeley PhD in Biochemistry.
Hirsh Goswamy
HEAD OF MARKETING
Marketing executive with track record of launching global brands with exponential growth. Fellow at OnDeck and Member Leader on Forbes Business Council. UC Berkeley.
Tatsuya Kuboi
HEAD OF BUSINESS DEVELOPMENT
Global business executive. Public accounting with KPMG & investment banking with Bank of America Securities. University of Washington & Stanford MBA.
Get in touch.
Have a question? Please fill out the form below, and we will respond to you as soon as possible. Inquiries are typically addressed within 3 business days. Thank you!